Jpmorgan Chase & CO Aquestive Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 31,834 shares of AQST stock, worth $154,394. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,834
Previous 102,419
68.92%
Holding current value
$154,394
Previous $436,000
81.19%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding AQST
# of Institutions
105Shares Held
43.1MCall Options Held
271KPut Options Held
212K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$47.6 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$26.9 Million1.58% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$26.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.23MShares$20.5 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.85MShares$13.8 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $259M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...